STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: These results indicated that CPT promoted the antileukemia effects of TKIs through decreasing the kinase activity of Bcr-Abl, and inhibiting STAT3 and eIF4E signalling pathways in resistant CML cell K562-R.